XRAY
Overvalued by 14.9% based on the discounted cash flow analysis.
Market cap | $6.64 Billion |
---|---|
Enterprise Value | $8.42 Billion |
Dividend Yield | $0.5726 (1.79%) |
Earnings per Share | $-0.62 |
Beta | 0.87 |
Outstanding Shares | 207,363,276 |
Avg 30 Day Volume | 5,232,312 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -50.3 |
---|---|
PEG | 9.2 |
Price to Sales | 1.6 |
Price to Book Ratio | 2.03 |
Enterprise Value to Revenue | 2.12 |
Enterprise Value to EBIT | 29.56 |
Enterprise Value to Net Income | -64 |
Total Debt to Enterprise | 0.25 |
Debt to Equity | 0.64 |
No data
No data